Document is current

Any future updates will be listed below

697 A phase 1 study of AMG 119, a DLL3-targeting, chimeric antigen receptor (CAR) T cell therapy, in relapsed/refractory small cell lung cancer (SCLC)

Crossref DOI link: https://doi.org/10.1136/jitc-2022-SITC2022.0697

Published Online: 2022-11-07

Published Print: 2022-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark